Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase ζ

Fig. 5

Cisplatin enhances the sensitivity of melanoma cells to PARP inhibitor olaparib. Five-day SRB growth assay on A375 melanoma cells in 96-well plates showing enhanced sensitivity to olaparib in the presence of 0.5 μM cisplatin. This cisplatin concentration is well below the IC50 value. In order to correct for the toxicity of cisplatin alone, for each curve growth is expressed as the percentage of the non-olaparib-treated control. Values plotted are mean % growth (±SEM) from three independent experiments

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us